Effect of low molecular weight heparin and ulinastatin as a combined therapy on soluble myeloid cell expression and intestinal mucosal function in patients with severe pancreatitis

Abstract

In the earlier published article, the ethical approval number of the Methods’ section was wrongly provided by the authors. The correct approval number should be: NKYY_YWKT_IRB_2021_009_01.
 New citation: Qian D, Luan X, Zhang Y. Effect of low molecular weight heparin and ulinastatin as a combined therapy on soluble myeloid cell expression and intestinal mucosal function in patients with severe pancreatitis. Trop J Pharm Res 2022; 21(7):1515-1521 doi: 10.4314/tjpr.v21i7.23 Erratum: 2022; 21(11): 2493 doi: http://dx.doi.org/10.4314/tjpr.v 21i11.32
 Earlier citation: Qian D, Luan X, Zhang Y. Effect of low molecular weight heparin and ulinastatin as a combined therapy on soluble myeloid cell expression and intestinal mucosal function in patients with severe pancreatitis. Trop J Pharm Res 2022; 21(7):1515-1521 doi: 10.4314/tjpr.v21i7.23